AstraZeneca (LON:AZN) Receives “Buy” Rating from Shore Capital

Shore Capital restated their buy rating on shares of AstraZeneca (LON:AZN) in a research report report published on Monday morning, MarketBeat Ratings reports.

Other research analysts also recently issued reports about the stock. Jefferies Financial Group reissued a hold rating and issued a £110 ($136.94) price target on shares of AstraZeneca in a report on Friday, February 16th. Berenberg Bank restated a buy rating on shares of AstraZeneca in a research note on Wednesday, March 13th. Barclays restated an overweight rating and issued a £125 ($155.61) price target on shares of AstraZeneca in a research note on Monday, April 8th. UBS Group lowered their price target on AstraZeneca from £107 ($133.20) to GBX 9,900 ($123.24) and set a sell rating on the stock in a report on Monday, February 12th. Finally, BMO Capital Markets reiterated an outperform rating on shares of AstraZeneca in a research report on Monday, February 12th. Two analysts have rated the stock with a sell rating, one has issued a hold rating and six have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, AstraZeneca has an average rating of Hold and an average target price of £115.43 ($143.69).

AstraZeneca Price Performance

AstraZeneca stock opened at £109.14 ($135.86) on Monday. AstraZeneca has a 52 week low of GBX 9,461 ($117.78) and a 52 week high of £123.92 ($154.26). The company’s 50 day moving average price is £103.35 and its two-hundred day moving average price is £104.24. The company has a quick ratio of 0.59, a current ratio of 0.82 and a debt-to-equity ratio of 75.70. The stock has a market cap of £169.17 billion, a P/E ratio of 3,638.28, a P/E/G ratio of 0.89 and a beta of 0.19.

AstraZeneca Increases Dividend

The business also recently disclosed a dividend, which was paid on Monday, March 25th. Stockholders of record on Thursday, February 22nd were issued a dividend of GBX 156 ($1.94) per share. The ex-dividend date was Thursday, February 22nd. This is a positive change from AstraZeneca’s previous dividend of $71.80. This represents a dividend yield of 1.49%. AstraZeneca’s payout ratio is 7,524.75%.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.